Australian Meningococcal Surveillance Programme Annual Report, 2022.

Q3 Medicine
Monica M Lahra, CR Robert George, Sebastiaan Van Hal, Tiffany R Hogan
{"title":"Australian Meningococcal Surveillance Programme Annual Report, 2022.","authors":"Monica M Lahra, CR Robert George, Sebastiaan Van Hal, Tiffany R Hogan","doi":"10.33321/cdi.2023.47.44","DOIUrl":null,"url":null,"abstract":"<p><p>In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). Compared to 2021, the number of IMD notifications in 2022 increased by 81% to 127, alongside the easing of COVID-19 containment measures. Laboratory confirmation occurred in 95% of these cases, with 51% (62/121) diagnosed by bacterial culture and 49% (59/121) by nucleic acid amplification testing. The serogroup was determined for 97% of laboratory-confirmed cases (117/121): serogroup B (MenB) accounted for 83% of infections (100/121); MenW for 4% (5/121); MenY for 10% (12/121); no infections were attributed to MenC disease. Fine typing was available on 67% of the cases for which the serogroup was determined (78/117). In MenB isolates, 27 porA types were detected, the most prevalent of which were P1.7-2,4 (18%;11/62), P1.22,14 (15%; 9/62), P1.18-1,34 (10%; 6/62) and P1.7,16-26 (10%; 6/62). All five MenW infections identified as porA type P1.5,2 with different MLST sequence types (ST): 11, 574, 1287, 12351, 13135 all belonging to clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY, the predominant porA type was P1.5-1,10-1 (73%; 8/11), ST 1655 and from clonal complex 23. Children less than 5 years of age and people aged 15-19 years were overrepresented with IMD notifications, accounting for 22% (27/121) and 23% (28/121) of laboratory-confirmed cases respectively. Fifteen percent of laboratory-confirmed notifications (18/121) were in persons aged 45-64 years. MenB infections were detected in all age groups but predominated in persons aged 15-19 years (93% of IMD in this age group; 26/28) and comprised 89% (24/27) of infections in children aged less than 5 years. MenW infections were markedly reduced in 2022, accounting for two IMD detections in children 1-4 years (2/16) and sporadic detections in other older age groups. MenY infections were largely detected in adults aged 45-64 years, accounting for 28% of IMD in this age group (5/18). All 62 cultured IMD isolates had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were categorised using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 5% (3/62) were defined as penicillin resistant (MIC value ≥ 0.5 mg/L); 71% (44/62) had intermediate susceptibility to penicillin (MIC values 0.125 and 0.25 mg/L) and 24% (15/62) were susceptible to penicillin. All isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"47 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable diseases intelligence (2018)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33321/cdi.2023.47.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). Compared to 2021, the number of IMD notifications in 2022 increased by 81% to 127, alongside the easing of COVID-19 containment measures. Laboratory confirmation occurred in 95% of these cases, with 51% (62/121) diagnosed by bacterial culture and 49% (59/121) by nucleic acid amplification testing. The serogroup was determined for 97% of laboratory-confirmed cases (117/121): serogroup B (MenB) accounted for 83% of infections (100/121); MenW for 4% (5/121); MenY for 10% (12/121); no infections were attributed to MenC disease. Fine typing was available on 67% of the cases for which the serogroup was determined (78/117). In MenB isolates, 27 porA types were detected, the most prevalent of which were P1.7-2,4 (18%;11/62), P1.22,14 (15%; 9/62), P1.18-1,34 (10%; 6/62) and P1.7,16-26 (10%; 6/62). All five MenW infections identified as porA type P1.5,2 with different MLST sequence types (ST): 11, 574, 1287, 12351, 13135 all belonging to clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY, the predominant porA type was P1.5-1,10-1 (73%; 8/11), ST 1655 and from clonal complex 23. Children less than 5 years of age and people aged 15-19 years were overrepresented with IMD notifications, accounting for 22% (27/121) and 23% (28/121) of laboratory-confirmed cases respectively. Fifteen percent of laboratory-confirmed notifications (18/121) were in persons aged 45-64 years. MenB infections were detected in all age groups but predominated in persons aged 15-19 years (93% of IMD in this age group; 26/28) and comprised 89% (24/27) of infections in children aged less than 5 years. MenW infections were markedly reduced in 2022, accounting for two IMD detections in children 1-4 years (2/16) and sporadic detections in other older age groups. MenY infections were largely detected in adults aged 45-64 years, accounting for 28% of IMD in this age group (5/18). All 62 cultured IMD isolates had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were categorised using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 5% (3/62) were defined as penicillin resistant (MIC value ≥ 0.5 mg/L); 71% (44/62) had intermediate susceptibility to penicillin (MIC values 0.125 and 0.25 mg/L) and 24% (15/62) were susceptible to penicillin. All isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin.

澳大利亚脑膜炎球菌监测计划年度报告,2022年。
在澳大利亚,侵袭性脑膜炎球菌病(IMD)的可能病例和实验室确诊病例都向国家法定疾病监测系统(NNDSS)报告。与2021年相比,随着新冠肺炎控制措施的放松,2022年IMD通知的数量增加了81%,达到127份。在这些病例中,95%发生了实验室确诊,51%(62/121)通过细菌培养诊断,49%(59/121)通过核酸扩增检测诊断。97%的实验室确诊病例(117/121)确定了血清组:B血清组(MenB)占感染的83%(100/121);MenW占4%(5/121);MenY占10%(12/121);没有任何感染归因于MenC疾病。67%的病例(78/117)可进行精细分型。在MenB分离株中,检测到27种porA类型,其中最常见的是P1.7-2,4(18%;11/62)、P1.22,14(15%;9/62)、P1.18-1,34(10%;6/62)和P1.7,16-26(10%;6/62)。所有五种MenW感染均被鉴定为P1.5型,2型porA,具有不同的MLST序列类型(ST):11,574,1287,12351,13135,均属于克隆复合体11,这是澳大利亚和海外疫情中报告的高毒力菌株。在MenY中,主要的porA类型是P1.5-1,10-1(73%;8/11)、ST 1655和来自克隆复合体23。5岁以下儿童和15-19岁人群在IMD通知中的比例过高,分别占实验室确诊病例的22%(27/121)和23%(28/121)。15%的实验室确认通知(18/121)发生在45-64岁的人群中。在所有年龄组中都检测到MenB感染,但主要发生在15-19岁的人群中(该年龄组IMD的93%;26/28),占5岁以下儿童感染的89%(24/27)。2022年,MenW感染显著减少,1-4岁儿童有两次IMD检测(2/16),其他老年组有零星检测。MenY感染主要发生在45-64岁的成年人中,占该年龄组IMD的28%(5/18)。所有62个培养的IMD分离株都进行了抗菌药物敏感性测试。使用临床实验室标准研究所(CLSI)的解释标准对最小抑菌浓度(MIC)值进行分类:5%(3/62)被定义为青霉素耐药性(MIC值≥0.5 mg/L);71%(44/62)对青霉素具有中等敏感性(MIC值0.125和0.25mg/L),24%(15/62)对盘尼西林敏感。所有分离株均对头孢曲松、环丙沙星和利福平敏感。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
72
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信